Conference Track

Investigational Antiretrovirals

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

HIV Integrase Inhibitor GSK364735 Well Tolerated in Healthy Individuals but Exposure Reduced with Coadministration of Antacid
XACT: Investigational CXCR4 Antagonist AMD11070 Active Against X4-Tropic Virus in Brief Monotherapy Setting
Investigational CXCR4 Antagonist AMD11070 Results in Reduced CXCR4 Signaling Following 10-Day Monotherapy in Patients With Dual/Mixed-Tropic HIV
Investigational Integrase Inhibitor Elvitegravir (GS-9137) Demonstrates Greater Week 24 Virologic Efficacy vs Control PIs in Treatment-Experienced Patients in Phase II Trial
Investigational NNRTI, TMC278, Shows Sustained Virologic and Immunologic Response Over 48 Weeks in Treatment-Naive Patients
In Vitro Study Suggests Viral Isolates Resistant to Elvitegravir (GS-9137) May Retain Susceptibility to Raltegravir (MK-0518)
Maraviroc Associated With Significant Virologic Suppression in Antiretroviral-Experienced Patients With CCR5-Tropic HIV
BENCHMRK-1 and -2: Raltegravir (MK-0518) Demonstrates Superior Efficacy and Similar Tolerability vs Placebo in Triple-Class–Resistant Patients at Week 16

Expert Analysis

Investigational Antiretroviral Agents for HIV-Infected Patients

Faculty:
Joseph J. Eron, Jr., MD Daniel R. Kuritzkes, MD William G. Powderly, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify agents in new classes of antiretroviral agents
Describe the results of recent studies of investigational antiretroviral agents
Discuss the implications of recent studies of investigational antiretroviral agents for patient management strategies

CME CREDIT INFORMATION

Release Date: 04/23/07

Expiration Date: 04/22/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.3 contact hours (0.13 CEUs)

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.